Neuro

Bioxodes presents BIOX-101 clinical data showing breakthrough potential for stroke in webcast with Prof Dr Robin Lemmens

Neuro by 0 comments

Gosselies, Belgium, 14 November 2025 (08:30 am CET) – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, has held a webcast on the breakthrough potential of its lead candidate BIOX101 to treat intracerebral hemorrhage (ICH) and discussed the data with Prof Dr Robin Lemmens, KU Leuven, the Principal Investigator of its Phase 2a BIRCH clinical trial. Prof Lemmens, a world-renowned stroke expert and head of the stroke unit at the University Hospital Leuven, underscored the urgent need to address the large unmet medical need in intracerebral hemorrhage, and provided his insights from the successful Phase 2a clinical study with BIOX-101. Bioxodes CEO Marc Dechamps presented the company’s strategy in bringing BIOX-101 to market, possibly as early as late 2030.

Continue Reading →

XCath Endovascular Robotic System Successfully Performs its First-In-Human Brain Aneurysm Procedures

Neuro by 0 comments

HOUSTON–(BUSINESS WIRE)–XCath, a medical device company dedicated to pioneering neuro-endovascular surgical robotics, announced today the successful first-in-human use of its EVR robotic system to treat three patients with complex brain aneurysms. The landmark procedures were performed at The Panama Clinic in Panama City, Panama, led by Vitor Mendes Pereira, M.D., […]

Continue Reading →

Kaneka Expands Global Reach with i-ED COIL™ Launch in Europe

Neuro by 0 comments

TOKYO–(BUSINESS WIRE)–Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) has begun sales of its i-ED COIL™, a brain aneurysm embolization coil (*1), in Europe as of October. The product obtained EC certification (*2) under an EU Medical Device Regulation (*3) in July and will be distributed primarily in Europe […]

Continue Reading →

Silver Creek Pharmaceuticals Announces Positive Phase 2 Results for Scp776 in Acute Ischemic Stroke

Neuro by 0 comments

Key Highlights Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up to 24 hours after onset) – a population with no approved drug options. Scp776 was safe and well-tolerated, with no increase in serious adverse events versus placebo. Scp776 leverages Silver Creek’s proprietary […]

Continue Reading →

Basking Biosciences Doses First Patients in Part B of Phase 2 Stroke Trial, Unlocks $27.5 Million Financing Tranche, and Appoints Julia C. Owens, Ph.D. as Chief Executive Officer

Financial Neuro by 0 comments

-Financing supports execution of Phase 2b RAISE trial evaluating BB-031, an investigational reversible thrombolytic for acute ischemic stroke, and the planned Phase 1 study of BB-025, its fast-acting reversal agent- -Current CEO Richard Shea transitions to President and Chief Operating…

Continue Reading →

Hyperfine Announces First Patients Enrolled in PRISM PMR to Evaluate the Use of Next-Generation Swoop® System in the Operating Room Setting

Neuro Radiology by 0 comments

With several patients already enrolled in the study, PRISM PMR is designed to evaluate the Swoop® system’s clinical utility in the operating room. GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® […]

Continue Reading →

Lumina 3D by RapidAI Named to TIME’s List of the Best Inventions of 2025

Neuro Radiology by 0 comments

SAN MATEO, Calif.–(BUSINESS WIRE)–RapidAI, the pioneer of deep clinical AI and the global leader in image-based decision support and workflow efficiencies, today announced that its Lumina 3D™ built on the Rapid Enterprise™ Platform has been named to TIME’s List of the Best Inventions of 2025, honoring 300 extraordinary innovations changing the […]

Continue Reading →
1 … 4 5 6 7 8 … 53